UNASSIGNED: In the HER2-positive group, 33 of 80 (41%) participants had their tumors shrink by 30% or more of their original size. In half of these participants, their tumors did not grow for 13 months or longer. No participant in the HER2-low group had their tumors shrink by 30% or more. In total, 63 of 87 participants (72%) had at least one side effect believed to be related to zanidatamab treatment. Most side effects were mild or moderate in severity. No participant died from complications related to zanidatamab. Diarrhea was one of the more common side effects and was experienced by 32 of 87 participants (37%). Side effects related to receiving zanidatamab through the vein, such as chills, fever, or high blood pressure, were experienced by 29 of 87 participants (33%).
UNASSIGNED: The results of this study support the potential for zanidatamab as a new therapy for people with HER2-positive biliary tract cancer after they had already received chemotherapy. More research is occurring to support these results.Clinical Trial Registration: NCT04466891 (HERIZON-BTC-01 study).
The HERIZON-BTC-01 study revealed zanidatamab as a potentially effective treatment for HER2-positive biliary tract cancer after standard chemotherapy fails. Read more in the lay summary by @hardingjjmd, @DrShubhamPant, and coauthors. #BiliaryTractCancer #HER2 #zanidatamab.
■在HER2阳性组中,80名参与者中有33名(41%)的肿瘤缩小了原始大小的30%或更多。在这些参与者中,有一半他们的肿瘤在13个月或更长时间内没有生长。低HER2组没有参与者的肿瘤缩小30%或更多。总的来说,87名参与者中有63名(72%)至少有一种副作用被认为与zanidatamab治疗有关。大多数副作用的严重程度为轻度或中度。没有参与者死于与zanidatamab相关的并发症。腹泻是较常见的副作用之一,87名参与者中有32名(37%)经历过。与通过静脉接受zanidatamab有关的副作用,如发冷,发烧,或者高血压,87名参与者中有29人(33%)经历过。
■这项研究的结果支持zanidatamab作为HER2阳性胆道癌患者已经接受化疗后的新疗法的潜力。正在进行更多的研究来支持这些结果。临床试验注册:NCT04466891(HERIZON-BTC-01研究)。
HERIZON-BTC-01研究表明,zanidatamab是标准化疗失败后HER2阳性胆道癌的潜在有效治疗方法。在@hardingjjmd的非专业摘要中阅读更多信息,@DrShubhamPant,和合著者。#BiliaryTractCancer#HER2#zanidatamab.